Safety of Oral JAK Inhibitors in Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis of 43 Real-World Studies.

IF 3.5 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of Evidence‐Based Medicine Pub Date : 2025-10-04 DOI:10.1111/jebm.70076

Hui Liu, Li Zhang, Huayu Zhang, Yuanyuan Yao, Wunan Huang, Dongrui Peng, Ye Wang, Yaxuan Ren, Hao Guo, Jibin Zhang, Yaolong Chen, Xinghua Gao

引用次数: 0

查看原文本刊更多论文

口服JAK抑制剂治疗炎症性皮肤病的安全性：43项真实世界研究的系统回顾和荟萃分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Evidence‐Based Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

11.20

自引率

1.40%

发文量

期刊介绍： The Journal of Evidence-Based Medicine (EMB) is an esteemed international healthcare and medical decision-making journal, dedicated to publishing groundbreaking research outcomes in evidence-based decision-making, research, practice, and education. Serving as the official English-language journal of the Cochrane China Centre and West China Hospital of Sichuan University, we eagerly welcome editorials, commentaries, and systematic reviews encompassing various topics such as clinical trials, policy, drug and patient safety, education, and knowledge translation.